Chemical Component Summary

NameLevobupivacaine
Synonyms(2~{S})-1-butyl-~{N}-(2,6-dimethylphenyl)piperidine-2-carboxamide
Identifiers(2~{S})-1-butyl-~{N}-(2,6-dimethylphenyl)piperidine-2-carboxamide
FormulaC18 H28 N2 O
Molecular Weight288.428
TypeNON-POLYMER
Isomeric SMILESCCCCN1CCCC[C@H]1C(=O)Nc2c(cccc2C)C
InChIInChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1
InChIKeyLEBVLXFERQHONN-INIZCTEOSA-N

Chemical Details

Formal Charge0
Atom Count49
Chiral Atom Count1
Bond Count50
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB01002 
NameLevobupivacaine
Groups
  • approved
  • investigational
DescriptionLevobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure to an anesthetic. Regardless, allergic reactions may also occur - although only rarely.
Synonyms
  • Levobupivacaína
  • Levobupivacaine hydrochloride
  • (S)-bupivacaine
  • (S)-1-butyl-2',6'-pipecoloxylidide
  • L-(−)-bupivacaine
IndicationFor the production of local or regional anesthesia for surgery and obstetrics, and for post-operative pain management
Categories
  • Amides
  • Amines
  • Anesthetics
  • Anesthetics, Local
  • Anilides
ATC-CodeN01BB10
CAS number27262-47-1

Drug Targets

NameTarget SequencePharmacological ActionActions
Sodium channel protein type 10 subunit alphaMEFPIGSLETNNFRRFTPESLVEIEKQIAAKQGTKKAREKHREQKDQEEK...unknowninhibitor
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 1A2MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1201193
PubChem 92253
ChEMBL CHEMBL1201193
ChEBI CHEBI:6149